Daniel O’Day is Chairman and CEO of Gilead Sciences. Like the thousands of other Gilead employees around the world, he is passionate about making the world a healthier, more equitable place for everyone. Daniel joined Gilead in 2019 and has led the company’s broader diversification into new cancer therapies and medicines for inflammatory diseases. The company has been a leader in virology for 30 years with a legacy that includes pioneering medicines for HIV, a cure for hepatitis C and, more recently, the first FDA-approved therapy for COVID-19. Daniel’s career also spans three decades with Hoffman La...read more